Research

Leaders in the Field

A pioneer in Lipoic Acid exploration, GeroNova is the only dietary supplement company currently sponsoring academic and clinical investigations with leading researchers and doctors worldwide. Our commitment to exploration has led to the development of the most stable, efficacious, and absorbable Lipoic Acid products available anywhere.

Our in-house exploration and development team specializes in organic synthesis, pharmacology, and nutraceutical product development, ensuring the highest levels of purity and consistency in our range of products. We actively partner with renowned scientists and medical professionals to continually advance our knowledge and provide the highest quality Lipoic Acid products. GeroNova is your premier source for all things related to this important component.

GeroNova’s Bio-Enhanced® R-Lipoic Acid (Na RALA) is a stabilized form of RLA designed for maximum bioavailability. Manufactured through a proprietary process that makes it more stable and easier to absorb, Bio-Enhanced® Na RALA has a higher concentration of active RLA compared to other forms. As a result, this facilitates the creation of more effective products. Learn More about our mission by visiting our

About Us Page.

Maximum Absorption
in mcg/mL

Research Articles

The Plasma Pharmacokinetics of
R-(+)-Lipoic Acid Administered as Sodium R-(+)-Lipoate to Healthy Human Subjects.

Carlson DA, Smith AR, Fischer SJ, Young KL, Packer L. Altern Med Rev 2007;12(4) 343-351

Therapeutic Potential of Lipoamide and Enhanced Mitochondrial Biogenesis for Treatment of Insulin Resistance

Shen W, Carlson DA, Packer L, Cadenas E, Liu J. Chapter 5 in Mitochondrial Signaling in Health and Disease (93-111) Eds. Orrenius S, Cadenas E and Packer L. CRC Press, Taylor & Francis Group, Boca Raton, London, New York (2012)

Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease

Maczurek A (b,c), Hager K (a), Kenlies M (a), Sharman M (d), Martins R (a), Engel J (e), Carlson DA (f), Münch G (b,c). Advanced Drug Delivery Reviews (2008)

Evaluation of the Role of Chirality and Amide Substitution in Redox Modulation of Signal Transduction by Lipoic Acid and Derivatives.

Poster Presentation, Oxygen Club of California, Alba, Italy June 20-23, 2012. Carlson DA.(1) He DY.(1) Kalashnikova E.(1) Gendelman R.(1, 2) Fischer SJ.(1), Packer L.(3)

Interaction of α-Lipoic Acid with the Human Na+/Multivitamin Transporter (hSMVT).

J Biol Chem. 2015 Jun 26;290(26):16372-82. doi: 10.1074/jbc.M114.622555. Epub 2015 May 13. Zehnpfennig B1, Wiriyasermkul P2, Carlson DA3, Quick M4.

A comparison of the pharmacokinetic profiles of lipoate enantiomers with the racemic mixture in healthy human subjects indicates possible stereoselective gut transport.

Carlson DA, Smith AR, Fischer SJ, Young KL.

Lipoic acid in Alzheimer’s disease – From basic therapeutic concepts to clinical trials

Marlies Kenklies, Klaus Hager, Gerald Münch, Shanmugam Kirubakaran, Annette Maczurek, Grant Stuchbury, David Carlson

The case against controlled release lipoic acid: A pharmacokinetic-mechanistic argument (part 1)

An Evaluation of the Stability and Pharmacokinetics of R-Lipoic Acid and R-Dihydrolipoic Acid Dosage Forms in Human Plasma from Healthy Subjects

David A. Carlson, Karyn L. Young, Sarah J. Fischer, and Heinz Ulrich

Send us a message